paracetamol overdose: evidence for early hepatocellular damage

Similar documents
hyperthyroidism and in hypothyroid patients receiving

A HISTOPATHOLOGICAL STUDY OF ANALGESIC HEPATOTOXICITY IN RABBIT

The Effects of Methionine on Paracetamol Induce Live Injury Hepatomegaly- (Animal Study)

EFFECTS OF MICROSOMAL ENZYME INDUCTION ON PARACETAMOL METABOLISM IN MAN

a Clinical Pharmacology Service and b Liver Unit, Hospital Universitario, School of

The predictive value of hospital admission serum alanine transaminase activity in patients treated for paracetamol overdose

The predictive value of serum alanine transaminase activity on first presentation to hospital in patients with paracetamol poisoning

This student paper was written as an assignment in the graduate course

epidemiological studies

A. J. HUSSEY, L. M. ALDRIDGE, D. PAUL, D. C. RAY, G. J. BECKETT AND L. G. ALLAN. Br. J. Anaesth. (1988), 60,

Measuring plasma paracetamol concentrations in all patients with drug overdose or altered consciousness: Does it change outcome?

Role of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):

Cimetidine Protects Against Acetaminophen Hepatotoxicity in Rats

Passage of paracetamol into breast milk and its subsequent metabolism by the neonate

Changes in paracetamol, antidepressants and opioid poisoning in Scotland during the 1990s

ABSTRACT 740 ACADEMIC EMERGENCY MEDICINE AUG 1996 VOL 3/NO 8

Acetylcysteine for Acetaminophen Poisoning

Early prediction of the outcome of a paracetamol

Anti-LSP antibodies in acute liver disease

coagulation defect of paracetamol-induced hepatic necrosis

Paracetamol Poisoning in Children

CHAPTER VII EFFECT OF H. ZEYLANICA, R. NASUTA AND S. CILIATA ON PARACETAMOL - INDUCED HEPATOTOXICITY IN WISTAR RATS

Long-term ingestion of paracetamol and liver disease'

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets

Paracetamol Overdose Clinical Audit

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

Chapter 143 Acetaminophen

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

The liver in poisoning: what can we learn from animal models?

Acetaminophen (APAP) is a safe analgesic at

Mechanism of Action of N-Acetylcysteine in the Protection Against the Hepatotoxicity of Acetaminophen in Rats In Vivo

Antiemetic Use in Acetaminophen Poisoning: How Does the Route of N-acetylcysteine Administration Affect Utilization?

Pharmacokinetic modelling of a high dose acetylcysteine regimen based on the SNAP trial

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES

DR J HARTY / DR CM RITCHIE / DR M GIBBONS

Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamolinduced hepatotoxicity

Serum microrna biomarkers for human DILI

Saião A, Chan B, Isbister GK Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, NSW Emergency Department, Prince of Wales

NEW ZEALAND DATA SHEET

DILI: Clinical Pharmacology Considerations for Risk Assessment

Pharmacokinetics of Acetaminophen Protein Adducts in Adults with. Acetaminophen Overdose and Acute Liver Failure

lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol

Chemically Reactive Drug Metabolites in Drug Discovery and Development Detection, Evaluation, and Risk Assessment

Acetaminophen (APAP: N-acetyl-para-aminophenol)

Paracetamol-Protein Adducts following Acute Paracetamol Overdose

Distribution of glutathione S-transferase isoenzymes in human kidney: basis for possible markers of renal injury

Hepatotoxicity and ALT/AST Enzymes Activities Change in Therapeutic and Toxic Doses Consumption of Acetaminophen in Rats

Evidence for the changing regimens of acetylcysteine

Acetaminophen (APAP: N-acetyl-para-aminophenol)

Glutathione S-transferase in humans in health and disease

Drug Induced Liver Injury (DILI)

Click to edit Master title style

Over-the-Counter Pain Management Gone Awry

Acute Chloroform Ingestion Successfully Treated with Intravenously Administered N-acetylcysteine

Summary of Product Characteristics

Metabolism Paracetamol is metabolised in the liver and excreted in the urine mainly as glucuronide and sulphate conjugates.

The protective effect of selenium nanoparticles and selenium against paracetamol

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre.

Chronic acetaminophen toxicity: lack of consensus

Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice

prevention of Acetaminophen and Cocaine Hepatotoxicity in Mice by Cimetidine Treatment

Summary of Product Characteristics

Simplified Gas Chromatographic Assay for Paracetamol

Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine

Does the patient history predict hepatotoxicity after acute paracetamol overdose?

HUMAN TOXICOLOGY Outcomes from massive paracetamol overdose: a retrospective observational study

King s College Hospital NHS Foundation Trust. Acute Liver Disease: what you really need to know.

... REPORTS... The Use and Effect of Analgesics in Patients Who Regularly Drink Alcohol. Richard C. Dart, MD, PhD

Acetaminophen (paracetamol) poisoning is the most. Acute Versus Chronic Alcohol Consumption in Acetaminophen-Induced Hepatotoxicity

Comparison of intramuscular glucagon and intravenous dextrose in the. accident and emergency department. treatment of hypoglycaemic coma in an

Current Concepts in Diagnosis and Management of Acute Liver Failure

THE NEW ZEALAND MEDICAL JOURNAL

KENNETH L. MULDREW, LAURA P. JAMES, LESLIE COOP, SANDRA S. MCCULLOUGH, HOWARD P. HENDRICKSON, JACK A. HINSON, AND PHILIP R. MAYEUX

α-glutathione S-Transferase: A New Biomarker for Liver Injury?

Leonard B. Seeff, M.D. Consultant Einstein Healthcare Network. Click to view Biosketch and Presentation Abstract or page down to review presentation

Protein isolate from the herb, Phyllanthus niruri, protects liver from acetaminophen induced toxicity

The biochemistry of acetaminophen hepatotoxicity and rescue: a mathematical model

PARENTERAL NUTRITION- ASSOCIATED LIVER DISEASE IN CHILDREN

Paracetamol poisoning in children and hepatotoxicity

Gamma-Glutamyl Transpeptidase and Other Liver Function Tests in Myocardial Infarction and Heart Failure

Interpreting Liver Function Tests

Acute appendicitis is a common condition and. Elevated serum bilirubin in acute appendicitis: A new diagnostic tool.

The dependence of paracetamol absorption on the rate of gastric emptying

UNUSUAL ACETAMINOPHEN TOXICITY SCENARIOS. Gosselin

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

Chapter 4. Drug Biotransformation

Professor Peter Hayes University of Edinburgh

Abnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University


ENZYME MARKERS OF TOXICITY

NEW ZEALAND DATASHEET

PHARMACOLOGY: DEFINITION: CHRONIC BRONCHITIS: CLINICAL USE:

SERUM CONCENTRATIONS OF COMPLEMENT COMPONENTS 3 AND 4 IN LIVER DISEASE

M6ller, McIntosh and Van Slyke (5) has been employed. The cases. changes in functional activity. Indications suggesting that such changes

PARACOD Tablets (Paracetamol + Codeine phosphate)

Acetaminophen Metabolism Does Not Contribute to Gender Difference in Its Hepatotoxicity in Mouse

Mechanistic Toxicology

Comparison of S-Adenosyl-L-methionine and N-Acetylcysteine Protective Effects on Acetaminophen Hepatic Toxicity

Supriya Sharma et al., Asian Journal of Pharmaceutical Technology & Innovation, 03 (14); 2015; Research Article

CLINICAL REVIEW. Management of paracetamol poisoning. Robin E Ferner, 1 2 James W Dear, 3 4 D Nicholas Bateman 3

Transcription:

Gut, 1985, 26, 26-31 Plasma glutathione S-transferase measurements after paracetamol overdose: evidence for early hepatocellular damage G J BECKETT, B J CHAPMAN, E H DYSON, AND J D HAYES From the University Department of Clinical Chemistry and Regional Poisoning Treatment Centre, The Royal Infirmary Edinburgh SUMMARY Plasma glutathione S-transferase (GST) measurements have been used to study early changes in hepatocellular integrity after paracetamol overdose and treatment with N- acetylcysteine (NAC). Patients admitted within seven hours and successfully treated had raised or equivocal GST on admission and each showed a transient peak in GST approximately 12 hours after the overdose. Similar, though smaller changes in GST, were seen in untreated patients whose paracetamol level fell below the treatment line. The plasma GST concentrations in successfully treated patients were small compared with values found in patients who subsequently developed severe liver damage. The changes in GST concentration observed in patients who developed severe liver damage indicated that distinct early and late phases of paracetamolinduced hepatotoxicity occurred. Although the mechanism by which paracetamol exerts its early toxic effect is unclear, our data suggest that prompt treatment with NAC can successfully prevent both clinical and subclinical hepatotoxicity in this early period. Paracetamol hepatotoxicity is caused by the production of an electrophilic arylating metabolite which binds covalently to macromolecules and initiates cell damage. This metabolite is normally rapidly inactivated by conjugation with glutathione but when the amount of paracetamol ingested is large, glutathione stores may be rapidly depleted and the toxic metabolite produces hepatocellular damage. 1 Paracetamol induced hepatotoxicity can be prevented by administration of compounds such as N-acetylcysteine (NAC) or methionine which replenish glutathione stores.i8 Such treatment is generally given to patients whose plasma paracetamol concentration, related to the time since ingestion, lies above a line joining semi-log plots of 200,ug/ml at 4 h and 30,ug/ml at 15 h.9 If treatment is not initiated in patients with plasma paracetamol concentrations which lie above the treatment line, or if it is delayed more than 10 to 12 hours after the overdose, severe liver damage will occur in approximately 60% of patients.9 The earliest biochemical Address for correspondence: Dr G J Beckett, University Department of Clinical Chemistry, The Royal Infirmary, Edinburgh EH3 9YW, Scotland. Received for publication 5 April 1984 26 evidence of acute liver damage becomes evident approximately 12 hours after the overdose but maximal abnormalities of liver function tests, particularly aspartate and alanine aminotransferase (AST and ALT) activity do not occur for two to four days. 10 The degree of liver damage is usually assessed by the plasma AST or ALT activity and severe liver damage is regarded as being present when plasma ALT or AST exceeds 1000 IU/1. In patients with moderate or mild degrees of paracetamol-induced hepatocellular damage, aminotransferase measurements may not reflect accurately the histological severity of liver damage.1' In contrast with AST, plasma concentrations of glutathione S-transferase (GST) correlate significantly with histology in patients with chronic active hepatitis. 12 The high concentration of GST in human liver cytosol and their small size (45 000/ 50 000 Da)13 suggest that plasma GST concentrations should provide a very sensitive index of hepatocellular integrity because after cellular damage, GST would be expected to be released quickly and in considerable quantity. Preliminary work has suggested that this is so.14 5 In the present study we have used GST measure-

Plasma glutathione S-transferase measurements after paracetamol overdose ments to investigate the time course of hepatocellular damage in patients admitted after paracetamol overdose. Methods PATIENTS Nineteen patients with paracetamol poisoning were studied. Seven did not require treatment and seven others were given NAC within eight hours of the overdose. Two patients were treated between 13 and 16 hours and three patients who presented after 17 hours were not treated. The alcohol intake before the overdose was noted in all patients. The plasma paracetamol concentrations and the ingestion treatment interval for each of the patients is shown in the Table. The treatment regime involved administering 300 mg/kg of NAC intravenously over a period of 20 hours.6 The first 150 mg/kg was given in 200 ml of 5% dextrose over 15 minutes followed by a 50 mg/kg dose in 500 ml of 5% dextrose over 4 hours and the two further 50 mg/kg doses each in 500 ml of 5% dextrose over the next two eight hour periods. Blood (10 ml) was taken on admission and at frequent intervals until discharge. In four patients blood was taken at 30 minute intervals for the first 14 hours after the initial rapid infusion of NAC. The plasma was assayed for ALT using a Sequential Multiple Analysis with Computer System (SMAC), Technicon. Instrument Corporation, Basingstoke, UK, and for GST by a specific radioimmunoassay.15 Interference in the radioimmunoassay in vitro by NAC was not seen until concentrations of NAC exceeded 50 g/l, concentrations which could not possibly be achieved in blood using the treatment regime described above. Reference ranges for ALT and GST were 10 to 40 IU/l and 0-5-30,ug/l respectively. Results NO TREATMENT GROUP Early presentation (<7 hours after overdose) Four of the seven patients with paracetamol concentrations below the treatment line had marginally raised GST concentrations on admission. In three of these patients GST concentrations rose further in the subsequent sample and in one patient, who had the highest paracetamol concentration of this group, this rise was marked (Fig. 1). Peak concentrations of GST were observed between four and 11 hours after the overdose and in all but one patient GST concentrations were normal on discharge. The rise in GST could not be attributed to acute alcohol ingestion because three of the four patients who Table Paracetamol levels and ingestion - treatment interval in the 19 patients. The Table shows the plasma paracetamol concentrations at the time shown in the second column. The ingestion-treatment interval and peak GSTandALTlevels are also shown. Plasma paracetamol Time after Ingestion-treatment Peak GST level Peak ALT level (1g/ml) ingestion (h) interval (h) (multiple of upper ref. value) Not treated - early presentation 92 6 5 NT 0 4 1.0 99 4-0 NT 1-4 0-4 111 45 NT 1-8 1.0 140 5-0 NT 0-6 0-4 160 4 0 NT 1-5 0-7 160 4-0 NT 0-8 0-7 163 4 0 NT 9-2 0-5 Not treated - late presentation 42 26-0 NT 3800 180 50 42-0 NT 630 58 57 18-0 NT 9900 222 Treated - early presentation 165 7 0 8-0 13-2 1-3 167 4-5 8-0 5-3 1-0 171 6-0 8-0 21-4 3-0 182 50 70 8-1 3-6 189 4 0 6-5 4-6 0-6 233 4 0 4-5 25 4 0-8 279 4-5 5-0 10-9 0-7 Treated - late presentation 55 12-0 13-0 3 700 280 109 15-0 16-0 10 700 470 NT = not treated. 27

28 k1 I0 0 5 10 15 20 25 30 35 Time after paracetamol overdose (h) Fig. 1 Plasma glutathione S-transferase (GST) concentrations in seven patients admitted with a paracetamol overdose but who did not require treatment. The dotted line represents the upper limit ofthe reference range. Aminotransferase measurements were normal in all samples. showed raised GST concentrations had taken no alcohol before the overdose. Normal activities of ALT were found in all samples from all these patients (Table). Late presentation (>17 hours after overdose) Three patients presented more than 17 hours after paracetamol overdose and each subsequently suffered severe liver damage with ALT activities >1000 IU/l (Fig. 2; Table). Each patients had GST concentrations on admission which were in excess of 150 times the upper limit of the reference range. In contrast ALT activities were no greater than 20 times the upper limit of the reference range. Each patient had raised but relatively stable GST concentrations (at 100-200 times the upper limit of the reference range) for a number of hours after admission. Between 38 hours and 45 hours, however, a further increase in GST concentrations occurred in two patients, with peak GST concentrations occurring between 50 hours and 70 hours. Peak concentrations of GST preceded peak activities of ALT by appoximately five hours to 10 hours and the relative magnitude of the abnormality of GST at these peak concentrations was between 10 and 30 times greater than for ALT. The fall in GST was far more rapid than the fall observed in ALT concentrations. TREATMENT GROUP Early presentaion (<7 hours after overdose) Each of the seven patients in this group had raised or equivocal GST on admission and all showed a peak in GST between six and 12 hours after the 0 41 e n t U C.5 a 0 JR Ia 0--- Beckett, Chapman, Dyson, and Hayes 501... 10 30 70 90 Time tter paracetcimod overdose (h) Fig. 2 Plasma glutathione S-transferase (GST) and alanine aminotransferase (ALT) concentrations in five patients who developed severe liver disease after a paracetamol overdose. Two patients (A and A) were treated with N-acetylcysteine at the times indicated by the arrows. The remaining three patients were admitted too late for treatment. overdose (Figs. 3 and 4). In all but two cases GST returned to normal within 24 hours. Only one patient admitted to consuming a large quantity of alcohol before taking the overdose. Three patients developed small abnormalities in ALT and AST which peaked 12 to 19 hours after the overdose. Two of the seven patients had half-hourly blood samples taken in the period immediately after the rapid infusion of NAC, and each showed a marked rise in GST concentration in the first postinfusion sample (Fig. 4). These abnormalities in GST rapidly reverted to normal. No abnormality in ALT or AST was seen in any sample taken from these two patients.

Plasma glutathione S-transferase measurements after paracetamol overdose Is a. t- I c VI '1 ALT 2j. _e" - _,. ------~. o 5 15 20 25 30 35 Time atter paracetamol overdose (h) Fig. 3 Plasma glutathione S-transferase (GST) and alanine aminotransferase (ALT) in five patients successfully treated with N-acetylcysteine, administered at the times indicated by the arrows. These patients did not develop liver damage. The dotted line represents the upper limit of the reference range. 0 5 10 15 20 25 30 35 Time after paracetamol overdose (h) Fig. 4 Acute changes in plasma glutathione S-transferase (GST) after treatment with N-acetylcysteine. The two patients were treated at the times indicated by the arrows. The dotted line represents the upper limit of the reference range. Aminotransferase measurements were normal in all samples. Late presentation (12-15 hours after overdose) Two patients who presented 12 and 15 hours after overdose were treated with NAC. In each of these patients the admission and subsequent GST concentrations were similar to those seen in the late presentation-untreated group. In both patients NAC treatment did not prevent liver damage and a large increase in GST and ALT was observed. Changes in GST concentrations appeared to occur in both patients after NAC infusion (Fig. 2). In one patient increased GST was observed in the first postinfusion sample and a peak in GST was observed one and half hours later. The changes in GST observed in the second patient were more difficult to interpret. In this patient GST did not rise in the first postinfusion sample but in the following hour there was a large rapid increase in GST. This patient quickly developed severe liver damage as shown by the rising ALT activities. The concentrations of GST also continued to rise, but a significant decrease in the rate of change of GST was observed one and a half hours after NAC infusion (Fig. 2). Discussion The data presented show the extreme sensitivity of GST measurements in detecting acute cellular damage. Sixteen of the 19 patients had abnormal GST concentrations. In contrast, ALT activity was raised only in eight patients. Large rises (>100 times normal values) in GST concentration were found on admission in all severely poisoned patients who were admitted more than 12 hours after taking paracetamol in overdose but such marked abnormalities in ALT activity were not noted until two days after the overdose. The high incidence of abnormal GST and low incidence of abnormal aminotransferase concentrations is consistent with the findings of James et all' who showed some degree of histological abnormality in 53 of 54 (98%) patients after paracetamol overdose only 24 (44%) of whom had abnormal AST activities. We have shown that, after paracetamol overdose, abnormal concentrations of GST can be observed within four hours of the overdose. In patients who are successfully treated with NAC, peak GST concentrations are much lower than those found in severely poisoned patients indicating that in treated patients early paracetamol toxicity is clinically insignificant. If NAC treatment is not given within eight hours, GST concentrations in excess of 100 times the upper limit of the reference range occur 12 to 40 hours after the overdose. A subsequent further marked increase in GST then occurs at 40-50 hours, 29

30 Beckett, Chapman, Dyson, and Hayes a rise which is consistent with previous findings that major liver damage occurs during this period.10 Our data, therefore, suggest that after a paracetamol overdose, in untreated patients, there are two distinct phases of hepatotoxicity. There is an early phase characterised by small abnormalities in plasma GST which occur within four hours and progress to more moderate abnormalites in plasma GST (approximately 100 times the upper limit of the reference range) by 40 hours. There then follows a second phase of hepatotoxicity characterised by severe liver damage and plasma GST concentrations in excess of 1000 times the upper limit of the reference range. The possibility of early liver.damage in patients taking a paracetamol overdose was first suggested by Prescott et al who noted that the plasma half life of paracetamol was prolonged from the outset in such patients.16 The early release of GST may be because of mild diffuse hepatocellular damage or may reflect damage to a specific population of cells which are more vulnerable to paracetamol. This putative increased vulnerability may be because of the increased concentrations of P450, subnormal intracellular concentrations of reduced glutathione or reduced conjugating ability. Whatever the cause, our data indicate that NAC treatment can arrest the early phase and prevent the late phase of paracetamol-induced hepatotoxicity. The rise in plasma GST which we observed within 30 minutes of NAC infusion may have been coincidental and caused solely by paracetamol toxicity but the time course of the rise in GST suggests that NAC treatment may itself result in a release of a small amount of GST from the hepatocyte in to plasma. Studies on isolated rat hepatocytes tend to support this view because high concentrations of cysteine, the active metabolite of NAC, can produce cytotoxicity and leakage of intracellular enzymes. 7 In man clarification of this point by control experiments - that is, NAC infusion in the absence of paracetamol poisoning and no NAC infusion after a paracetamol overdose, in patients requiring treatment and admitted within 8 hours - would be unethical. Comparison of peak GST values found in severe paracetamol-induced liver damage with peak values found in successfully treated patients indicates, however, that any liver damage resulting from NAC infusion is, clinically, insignificant. It should be noted that GST is present in renal tissue in a concentration similar to that found in liver. 18 It is likely, therefore, that a small percentage of the GST we have measured in plasma is of renal origin. In conclusion, although the mechanism by which paracetamol exerts an early toxic effect on the liver is unclear, our data suggest that prompt treatment with NAC can successfully prevent both clinical and subclinical hepatotoxicity in this early period. It would be useful to ascertain whether methionine, the other commonly used treatment for paracetamol overdose7 8 is as effective at preventing this early toxicity. Our data also show the sensitivity and potential which plasma GST measurements have in investigating, non-invasively, hepatotoxicity We would like to thank Drs L F Prescott and A T Proudfoot for their advice and for allowing us to study patients under their care. We would also like to thank Professor L G Whitby and Dr A F Smith for their valuable help in the preparation of this manuscript and Mrs E Ward for her secretarial assistance. This work was supported by a grant from the Scottish Home and Health Department. References 1 Mitchell JR, Jollow DJ, Potter WZ, Davies DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973; 187: 185-94. 2 Jollow DJ, Mitchell JR, Potter WZ, Davies DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973; 187: 195-202. 3 Potter WZ, Davies DC, Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther 1973; 187: 203-10. 4 Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973; 187: 211-7. 5 Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977; 2: 432-4. 6 Prescott LF, Illingworth RN, Critchley JAJH, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N- acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2: 1097-100. 7 Prescott LF, Park J, Sutherland GR, Smith IJ, Proudfoot AT. Cysteamine, methionine and penicillamine in the treatment of paracetamol poisoning. Lancet 1976; 2: 109-13. 8 Vale JA, Meredith TJ, Goulding R. Treatment of acetaminophen poisoning. Arch Intern Med 1981; 141: 394-6. 9 Prescott LF, Critchley JAJH. The treatment of acetaminophen poisoning. Ann Rev Pharmacol Toxicol 1983; 23: 87-101.

Plasma glutathione S-transferase measurements after paracetamol overdose 31 10 Proudfoot AT, Wright N. Acute paracetamol poisoning. Br Med J 1970; 4: 557-8. 11 James 0, Lesna M, Roberts SH et al. Liver damage after paracetamol overdose: comparison of liver function tests, fasting serum bile acids and liver histology. Lancet 1975; 2: 579-81. 12 Sherman M, Bass NM, Campbell JAH, Kirsch RE. Radioimmunoassay of human ligandin. Hepatology 1983; 3: 162-9. 13 Jakoby WB, Habig WH. Glutathione transferases. In: Jakaboy WB, ed. Enzymatic basis of detoxication. Vol 2. London: Academic Press, 1980: 63-94. 14 Bass NM, Kirsch RE, Tuff SA, Saunders SJ. Radioimmunoassay of plasma ligadin. Gastroenterology 1978; 75: 589-94. 15 Hayes JD, Gilligan D, Chapman BJ, Beckett GJ. Purification of human hepatic glutathione S- transferases and the development of a radioimmunoassay for their measurement in plasma. Clin Chim Acta 1983; 134: 107-21.. 16 Prescott LF, Wright N, Roscoe P, Brown SS. Plasmaparacetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet 1971; 1: 519-22. 17 Vina J, Saez GT, Wiggins D, Roberts AFC, Hems R, Krebs HA. The effect of cysteine oxidation on isolated hepatocytes. Biochem J 1983; 212: 39-44. 18 Koskelo K..Isoelectric focusing of glutathione S- transferase: Comparison of the acidic transferases from human liver, kidney, lung, spleen and placenta. Scand J Clin Lab Invest 1983; 43: 133-9. Gut: first published as 10.1136/gut.26.1.26 on 1 January 1985. Downloaded from http://gut.bmj.com/ on 15 January 2019 by guest. Protected by copyright.